About Verdiva Bio

Verdiva Bio develops targeted therapies that enhance metabolic function and weight management in patients with obesity and cardiometabolic diseases. Their treatments focus on improving insulin sensitivity and reducing inflammation, leading to better health outcomes for affected individuals.

```xml <problem> Obesity and cardiometabolic disorders represent a significant and growing global health challenge. Current therapeutic options often fail to provide patient-friendly solutions that effectively address the underlying metabolic dysfunction and related complications. </problem> <solution> Verdiva Bio is developing a portfolio of next-generation therapies designed to improve outcomes for individuals with obesity, cardiometabolic disorders, and associated complications. Their approach leverages emerging science in gut-brain biology to create differentiated medicines that target unmet needs in this space. The company's lead therapy, VRB-101, is an oral GLP-1 peptide agonist in clinical development, demonstrating potential for compelling efficacy with a convenient once-weekly dosing regimen. Verdiva Bio is also advancing multiple amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs, all aimed at achieving enhanced efficacy, improved tolerability, and healthier weight loss profiles. These therapies are being developed both as monotherapies and in combination to address the complex needs of patients with cardiometabolic diseases. </solution> <features> - VRB-101: An oral, once-weekly GLP-1 receptor agonist in Phase 1 clinical development for obesity. - VRB-103: An oral, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with oral GLP-1 therapy. - VRB-102: An injectable, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with VRB-101. - Oral and subcutaneous amylin agonists with the potential for enhanced efficacy and improved tolerability. - Combination therapies of GLP-1 and amylin agonists for synergistic effects on weight loss and metabolic function. </features> <target_audience> The primary target audience includes individuals with obesity, cardiometabolic disorders, and related complications, as well as healthcare providers specializing in endocrinology, cardiology, and metabolic health. </target_audience> ```

What does Verdiva Bio do?

Where is Verdiva Bio located?

Verdiva Bio is based in London, United Kingdom.

When was Verdiva Bio founded?

Verdiva Bio was founded in 2024.

How much funding has Verdiva Bio raised?

Verdiva Bio has raised 410000000.

Location

London, United Kingdom

Founded

2024

Funding

410000000

Employees

28 employees

Major Investors

General Atlantic, Forbion Capital Partners

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Verdiva Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

verdivabio.com 2K+

Crunchbase

Founded 2024 – London, United Kingdom

Funding

Estimated Funding

$200M+

Major Investors

General Atlantic, Forbion Capital Partners

Team (25+)

No team information available.

Company Description

Problem

Obesity and cardiometabolic disorders represent a significant and growing global health challenge. Current therapeutic options often fail to provide patient-friendly solutions that effectively address the underlying metabolic dysfunction and related complications.

Solution

Verdiva Bio is developing a portfolio of next-generation therapies designed to improve outcomes for individuals with obesity, cardiometabolic disorders, and associated complications. Their approach leverages emerging science in gut-brain biology to create differentiated medicines that target unmet needs in this space. The company's lead therapy, VRB-101, is an oral GLP-1 peptide agonist in clinical development, demonstrating potential for compelling efficacy with a convenient once-weekly dosing regimen. Verdiva Bio is also advancing multiple amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs, all aimed at achieving enhanced efficacy, improved tolerability, and healthier weight loss profiles. These therapies are being developed both as monotherapies and in combination to address the complex needs of patients with cardiometabolic diseases.

Features

VRB-101: An oral, once-weekly GLP-1 receptor agonist in Phase 1 clinical development for obesity.

VRB-103: An oral, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with oral GLP-1 therapy.

VRB-102: An injectable, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with VRB-101.

Oral and subcutaneous amylin agonists with the potential for enhanced efficacy and improved tolerability.

Combination therapies of GLP-1 and amylin agonists for synergistic effects on weight loss and metabolic function.

Target Audience

The primary target audience includes individuals with obesity, cardiometabolic disorders, and related complications, as well as healthcare providers specializing in endocrinology, cardiology, and metabolic health.